Multimarker quantitative real-time PCR detection of circulating melanoma cells in peripheral blood: relation to disease stage in melanoma patients
- PMID: 15817820
- PMCID: PMC2856477
- DOI: 10.1373/clinchem.2004.045096
Multimarker quantitative real-time PCR detection of circulating melanoma cells in peripheral blood: relation to disease stage in melanoma patients
Abstract
Background: Detection of melanoma cells in circulation may be important in assessing tumor progression. The objective of this study was to develop a specific, reliable multimarker quantitative real-time reverse transcription-PCR (qRT) assay for detecting melanoma cells in patients' blood.
Methods: We developed qRT assays for the mRNA of four melanoma-associated markers: MART-1, GalNAc-T, PAX-3, and MAGE-A3. In optimization studies, we tested 17 melanoma cell lines and 49 peripheral blood leukocyte (PBL) samples from volunteers. We performed RNA and melanoma cell dilution studies to assess the detection limits and imprecision of the assays. We measured the mRNAs in blood specimens from 94 melanoma patients [American Joint Committee on Cancer (AJCC) stage I, n = 20; II, n = 20; III, n = 32; IV, n = 22].
Results: All markers were frequently detected in melanoma cell lines, whereas none of the markers was detected in PBLs from volunteers. The qRT assay could detect 1 melanoma cell in 10(7) PBLs in the melanoma cell-dilution studies. Markers were detected in 15%, 30%, 75%, and 86% of melanoma patients with AJCC stage I, II, III, and IV disease, respectively. The number of positive markers and AJCC stage were significantly correlated (Spearman correlation coefficient = 0.58; P < 0.0001).
Conclusions: Multimarker qRT can detect circulating melanoma cells in blood. Measurement of the studied molecular markers in blood may be useful in detection of metastasis and monitoring treatment response of melanoma patients.
Figures


Similar articles
-
Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trial.J Clin Oncol. 2005 Nov 1;23(31):8057-64. doi: 10.1200/JCO.2005.02.0958. J Clin Oncol. 2005. PMID: 16258104 Free PMC article.
-
Molecular staging of pathologically negative sentinel lymph nodes from melanoma patients using multimarker, quantitative real-time rt-PCR.Ann Surg Oncol. 2009 Jan;16(1):177-85. doi: 10.1245/s10434-008-0183-9. Epub 2008 Nov 4. Ann Surg Oncol. 2009. PMID: 18982394
-
Molecular upstaging based on paraffin-embedded sentinel lymph nodes: ten-year follow-up confirms prognostic utility in melanoma patients.Ann Surg. 2011 Jan;253(1):116-22. doi: 10.1097/SLA.0b013e3181fca894. Ann Surg. 2011. PMID: 21135695 Free PMC article.
-
Prognostic value of circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction.J Clin Oncol. 2003 Mar 1;21(5):767-73. doi: 10.1200/JCO.2003.01.128. J Clin Oncol. 2003. PMID: 12610172 Review.
-
The clinical utility of multimarker RT-PCR in the detection of occult metastasis in patients with melanoma.Recent Results Cancer Res. 2001;158:78-92. doi: 10.1007/978-3-642-59537-0_8. Recent Results Cancer Res. 2001. PMID: 11092035 Review.
Cited by
-
Microphthalmia transcription factor as a molecular marker for circulating tumor cell detection in blood of melanoma patients.Clin Cancer Res. 2006 Feb 15;12(4):1137-43. doi: 10.1158/1078-0432.CCR-05-1847. Clin Cancer Res. 2006. PMID: 16489066 Free PMC article.
-
Prognostic relevance of occult nodal micrometastases and circulating tumor cells in colorectal cancer in a prospective multicenter trial.Clin Cancer Res. 2008 Nov 15;14(22):7391-6. doi: 10.1158/1078-0432.CCR-08-0290. Clin Cancer Res. 2008. PMID: 19010855 Free PMC article. Clinical Trial.
-
PAX3 expression in normal skin melanocytes and melanocytic lesions (naevi and melanomas).PLoS One. 2010 Apr 22;5(4):e9977. doi: 10.1371/journal.pone.0009977. PLoS One. 2010. PMID: 20421967 Free PMC article.
-
PAX3 expression patterns in ocular surface melanocytes.Sci Rep. 2025 Apr 11;15(1):12472. doi: 10.1038/s41598-025-90318-3. Sci Rep. 2025. PMID: 40216818 Free PMC article.
-
Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trial.J Clin Oncol. 2005 Nov 1;23(31):8057-64. doi: 10.1200/JCO.2005.02.0958. J Clin Oncol. 2005. PMID: 16258104 Free PMC article.
References
-
- Greene FL, Fleming ID, Fritz AG, Balch CM, Haller DG, Morrow M. AJCC cancer staging manual. 6th ed. New York: Springer-Verlag; 2002.
-
- Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19:3635–3648. - PubMed
-
- Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, et al. New TNM melanoma staging system: linking biology and natural history to clinical outcomes. Semin Surg Oncol. 2003;21:43–52. - PubMed
-
- Pantel K, Cote RJ, Fodstad O. Detection and clinical importance of micrometastatic disease. J Natl Cancer Inst. 1999;91:1113–1124. - PubMed
-
- Hoon DS, Bostick P, Kuo C, Okamoto T, Wang HJ, Elashoff R, et al. Molecular markers in blood as surrogate prognostic indicators of melanoma recurrence. Cancer Res. 2000;60:2253–2257. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical